95 related articles for article (PubMed ID: 11365782)
1. Stopping CMV prophylaxis with HAART.
TreatmentUpdate; 1998 Sep; 10(7):4-6. PubMed ID: 11365782
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.
Jacobson MA; Zegans M; Pavan PR; O'Donnell JJ; Sattler F; Rao N; Owens S; Pollard R
Lancet; 1997 May; 349(9063):1443-5. PubMed ID: 9164318
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
Whitcup SM
JAMA; 2000 Feb; 283(5):653-7. PubMed ID: 10665706
[TBL] [Abstract][Full Text] [Related]
4. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy.
Macdonald JC; Torriani FJ; Morse LS; Karavellas MP; Reed JB; Freeman WR
J Infect Dis; 1998 May; 177(5):1182-7. PubMed ID: 9593001
[TBL] [Abstract][Full Text] [Related]
5. Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy.
Di Perri G; Vento S; Mazzi R; Bonora S; Bonora A; Trevenzoli M; Allegranzi B; Carretta G; Lanzafame M; Pizzighella S; Concia E
J Infect; 1999 Nov; 39(3):193-7. PubMed ID: 10714794
[TBL] [Abstract][Full Text] [Related]
6. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease.
Verbraak FD; Boom R; Wertheim-van Dillen PM; van den Horn GJ; Kijlstra A; de Smet MD
Br J Ophthalmol; 1999 Oct; 83(10):1186-9. PubMed ID: 10502584
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts.
Vrabec TR; Baldassano VF; Whitcup SM
Ophthalmology; 1998 Jul; 105(7):1259-64. PubMed ID: 9663231
[TBL] [Abstract][Full Text] [Related]
8. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy.
Torriani FJ; Freeman WR; Macdonald JC; Karavellas MP; Durand DM; Jeffrey DD; Meylan PR; Schrier RD
AIDS; 2000 Jan; 14(2):173-80. PubMed ID: 10708288
[TBL] [Abstract][Full Text] [Related]
9. Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis: long-Term results in a small case series.
Reed JB; Briggs JW; McDonald JC; Freeman WR; Morse LS
Retina; 2001; 21(4):339-43. PubMed ID: 11508879
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy.
Berenguer J; González J; Pulido F; Padilla B; Casado JL; Rubio R; Arribas JR;
Clin Infect Dis; 2002 Feb; 34(3):394-7. PubMed ID: 11753827
[TBL] [Abstract][Full Text] [Related]
11. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy.
Song MK; Karavellas MP; MacDonald JC; Plummer DJ; Freeman WR
Retina; 2000; 20(2):151-5. PubMed ID: 10783947
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.
Jouan M; Savès M; Tubiana R; Carcelain G; Cassoux N; Aubron-Olivier C; Fillet AM; Nciri M; Sénéchal B; Chêne G; Tural C; Lasry S; Autran B; Katlama C;
AIDS; 2001 Jan; 15(1):23-31. PubMed ID: 11192865
[TBL] [Abstract][Full Text] [Related]
13. Protease inhibitors linked to drop in CMV retinitis.
AIDS Alert; 1997 Aug; 12(8):92-4. PubMed ID: 11364475
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic manifestations of HIV in the highly active anti-retroviral therapy era.
Mowatt L
West Indian Med J; 2013; 62(4):305-12. PubMed ID: 24756590
[TBL] [Abstract][Full Text] [Related]
15. Sustained cytomegalovirus-specific CD4+ T cell response associated with prevention of recurrence of cytomegalovirus retinitis without secondary prophylaxis after highly active antiretroviral therapy in patients with AIDS.
Tanaka M; Yasuoka C; Genka I; Tachikawa N; Kikuchi Y; Teruya K; Yasuoka A; Hirabayashi Y; Kimura S; Oka S
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1749-56. PubMed ID: 11788026
[TBL] [Abstract][Full Text] [Related]
16. Control of cytomegalovirus retinitis after combination antiretroviral therapy.
Ruhswurm I; Ries E; Krepler K; Derbolav A; Rieger A; Armbruster C; Wedrich A
Acta Ophthalmol Scand; 1999 Aug; 77(4):471-3. PubMed ID: 10463426
[TBL] [Abstract][Full Text] [Related]
17. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
Komanduri KV; Feinberg J; Hutchins RK; Frame RD; Schmidt DK; Viswanathan MN; Lalezari JP; McCune JM
J Infect Dis; 2001 Apr; 183(8):1285-9. PubMed ID: 11262214
[TBL] [Abstract][Full Text] [Related]
18. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
Green H; Hay P; Dunn DT; McCormack S;
HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
[TBL] [Abstract][Full Text] [Related]
19. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment.
Jabs DA; Van Natta ML; Thorne JE; Weinberg DV; Meredith TA; Kuppermann BD; Sepkowitz K; Li HK;
Ophthalmology; 2004 Dec; 111(12):2232-9. PubMed ID: 15582079
[TBL] [Abstract][Full Text] [Related]
20. Cessation of anti-CMV therapy in patients with CMV retinitis.
Dunn JP
Hopkins HIV Rep; 1998 Mar; 10(2):11. PubMed ID: 11365137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
